Device Trial Radar · NCT03150407
Use of J3 Bioscience Lubricating Intravaginal Ring VR101 to Relieve the Symptoms of Vaginal Dryness
Last checked: Nov 19, 2026Latest source record: Nov 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
May 1, 2017
Primary completion
Aug 31, 2017
Study completion Nov 30, 2017
Sponsor
- Lead sponsor
- J3 Bioscience, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Advanced Clinical Research Services, LLC; Phil Triolo and Associates LC
- First posted
- May 12, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Female only, from 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This investigation is designed to demonstrate the safety and efficacy of the VR101 lubricating intravaginal ring (IVR) in treating the symptoms of vaginal dryness. In the proposed investigation, participants will use VR101 devices and sham control rings in a crossover study design. All participants who successfully complete the crossover study will be given the option to continue using VR101 for a total of 13 consecutive weeks to evaluate the long-term safety of the new device.
Conditions
- Menopause Related Conditions
- Postmenopausal Symptoms
Interventions
VR101 Device (Efficacy)Device
Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days
Sham Control RingOther
Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days
VR101 Device (Safety)Device
Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of VR101 Treatments at 28 Days Assessed by Change in VHI (Vaginal Health Index) Scores Assigned by CliniciansTime frame: Baseline, 28 Days
- Serious Adverse Device EffectsTime frame: Up to 24 weeks total, comprising up to 17 weeks total VR101 use and up to 4 weeks total sham control use.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Advanced Clinical Research, Inc. (ACR Idaho)
Meridian, Idaho
Advanced Clinical Research, Inc. (ACR Utah)
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.